| INDIVIOR PHARMACEUTICALS |
| USA |
| Gesundheit |
| US45579U1097 / A42086 |
| E7P (Frankfurt) / INDV (NASDAQ) |
| FRA:E7P, ETR:E7P, E7P:GR, NASDAQ:INDV |
| - |
| https://www.indivior.com/ |
|
Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on treating substance use disorders and related mental health conditions. The company concentrates on evidence-based therapies for opioid use disorder, including long-acting..
>Volltext.. |
| 4255.04 Mio. EUR |
| 4544.13 Mio. EUR |
| 1120.23 Mio. EUR |
| 394.81 Mio. EUR |
| 217.8 Mio. EUR |
| 1.75 EUR |
| 441.67 Mio. EUR |
| 151.85 Mio. EUR |
| -96.53 Mio. EUR |
| 0.22 |
| 3.32% |
| - |
| - |
| - |
| - |
| 16.06.16 - 2.0083€ 17.09.15 - 0.67648€ |
| INDIVIOR |
| 03.08.26 |
|